Literature DB >> 28289584

Mutation analysis of the NRXN1 gene in autism spectrum disorders.

H Onay1, D Kacamak2, A N Kavasoglu1, B Akgun1, M Yalcinli1, S Kose1, B Ozbaran1.   

Abstract

The aim of this study was to identify the sequence mutations in the Neurexin 1 (NRXN1) gene that has been considered as one of the strong candidate genes. A total of 30 children and adolescents (aged 3-18) with non syndromic autism were enrolled this study. Sequencing of the coding exons and the exon-intron boundaries of the NRXN1 gene was performed. Two known mutations were described in two different cases. Heterozygous S14L was determined in one patient and heterozygous L748I was determined in another patient. The S14L and L748I mutations have been described in the patients with autism before. Both of these mutations were inherited from their father. In this study, two of 30 (6.7%) autism spectrum disorder (ASD) patients carrying NRXN1 gene mutations were detected. It indicates that variants in the NRXN1 gene might confer a risk of developing nonsyndromic ASD. However, due to the reduced penetrance in the gene, the causal role of the NRXN1 gene mutations must be evaluated carefully in all cases.

Entities:  

Keywords:  Autism spectrum disorder (ASD); Mutation; Neurexin 1 (NRXN1) gene; Sanger sequencing

Year:  2017        PMID: 28289584      PMCID: PMC5343326          DOI: 10.1515/bjmg-2016-0031

Source DB:  PubMed          Journal:  Balkan J Med Genet        ISSN: 1311-0160            Impact factor:   0.519


Introduction

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is characterized by persistent impairment in reciprocal social communication and social interaction, and restricted, repetitive patterns of behavior, interests, or activities, and with increasing prevalence in recent years [1]. Prevalence ratio of ASD was stated to be in the range of 0.6 to 2.64% [2-3]. A male predominance was observed and male-to-female ratio was 5 [4]. There is no accurate etiological factor that causes ASD; however ASD is likely to result from a complex interaction between genetic and environmental factors [3-5]. Autism spectrum disorder is one of the most heritable psychiatric disorders and heritability of ASD is 90.0% [6]. There is an increased recurrence risk of more than 20-fold in first-degree relatives [7]. Comprehensive genetic testing of children with ASD revealed a chromosomal or mendelian cause in 15.0-40.0% of the patients [8]. Classifying autism into ‘essential’ and ‘complex’ subgroups may be beneficial to understanding the genetic basis of the disorder [9]. Essential autism is usually present in about 75.0% of cases and is characterized by absence of dysmorphic features and comorbidities. In this group, there is a higher male-to-female ratio and higher sibling recurrence risk compared to the complex autism. In complex or syndromic autism, some dysmorphic features and neurological and medical symptoms such as seizures accompany autism. Because of the comorbidities, prognosis is worse in this group. The distinction between the two types of autism is important because prognosis, recurrence risk and genetic approach are different between the two groups [10]. Understanding the genetic basis of autism is challenging. The genetics of autism is an active research area and up to now, nearly all kinds of study designs have been used including family based, case-control, genome wide association studies (GWAS) and next generation sequencing (NGS). All these genetic studies reported that more than 600 genes and 2000 loci have been related to ASD and 83.4% of the detected variants are rare variants [11]. Genetic variations detected in ASD can be classified into three subgroups: in up to 5.0% of the cases, cytogenetic anomalies can be detected with standard karyotyping, and an additional 3.0-5.0% have been found using fluorescence in situ hybridization (FISH); in 10.0-35.0% of cases, copy number variants (CNVs) can be found with microarray analysis and in 5.0% of the cases, single gene mutations might be found [10]. In the complex/syndromic autism group, it is relatively easier to find the genetic etiology with the help of dysmorphic features. Fragile X syndrome, Angelman syndrome or Rett syndrome are examples of syndromic ASD. Approximately 1.0-3.0% of children with ASD have been found to have fragile X syndrome. A considerable number of children being evaluated for autism FMR1 premutations (55-200 CGG repeats) have also been found [10]. In the essential autism group, many genes have been blamed, and the likelihood of identifying a single gene mutation in an essential autism patient is extremely low. SFARIGENE [11] (https://gene.sfari.org) is a web-based database of candidate genes associated with ASD and all the genes annotated in this database are grouped in seven categories according to their relevance to ASD. A number of these genes are becoming clinically relevant. Especially the genes associated with the synaptic cell adhesion and synaptic function, such as neurexin 1 (NRXN1), neuroligin 3 (NLGN3), neuroligin 4 (NLGN4) and SHANK3 have attracted great attention. Neurexins function in the vertebrate nervous system as cell adhesion molecules and receptors. Neuroxin 1 is a cell surface receptor that binds neuroligins to form a calcium-dependent neurexin/neuroligin complex at synapses in the central nervous system (CNS). This complex is important for efficient neuro transmission and is involved in the formation of synaptic contacts [12]. The NRXN1 gene is listed as a strong candidate gene in the SFARIGENE database and heterozygous deletions, and up to now, point mutations have been detected in the NRXN1 gene in a limited number of patients with ASD [11]. Herein, in order to investigate the prevalence of NRXN1 mutations in ASD patients, sequencing of the NRXN1 gene was performed in 30 essential ASD patients with a normal karyotype and negative FMR1 analysis for fragile X syndrome.

Materials and Methods

Thirty children and adolescents (aged 3-18) diagnosed with autism, who were followed at the Ege University Child and Adolescent Psychiatry Clinic, Autism and Developmental Disorders Department, Ege University School of Medicine, Izmir, Turkey, were included in this study. The patientsautism diagnosis was made using (DSM-IV-TR) [13] criteria by two expert child and adolescent psychiatrists, who have been working in the autism area for the past 15 years. The Childhood Autism Rating Scale (CARS) Turkish Version [14,15] was used for all children in this study. The CARS is widely used to determine the presence and degree of autism. The CARS is an autism diagnostic schedule covering 14 functional areas that may be compromised in autism, and a final general category referring to ‘degree of autism’ [14]. The 15 items in the scale are: relating to people; imitative behavior; emotional response; body use; object use; adaptation to change; visual response; listening response; perceptive response; fear or anxiety; verbal communication; non-verbal communication; activity level; level and consistency of intellective relations; general impressions. The examiner assigned a score of 1 to 4 for each item: 1 indicates behavior appropriate for age level, while 4 indicates severe deviance with respect to normal behavior for age level. The total score range is between 15 and 60. Scores of 30 to 36 indicate mild to moderate autism and scores above 36 indicate severe autism. Chromosomal abnormalities and fragile X syndrome were excluded in all patients by karyotyping and FMR1 gene CGG expansion analysis, respectively. The NRXN1 gene mutation analysis was performed by sequencing of the coding exons and exon-intron boundaries of the gene at the Department of Medical Genetics, Molecular Genetics Laboratory, Ege University, Izmir, Turkey. Genomic DNA was isolated from peripheral blood cells by standard techniques. All polymerase chain reaction (PCR) products were sequenced by the BigDye termination method using a DNA sequencing kit (Perkin-Elmer, Foster City, CA, USA) and analyzed using The ABI PRISM® 3100 sequence analyzer (Applied Biosystems, Foster City, CA, USA).

Results

Thirty patients were included in this study. Twenty-five (83.3%) were boys and five (16.7%) were girls. The mean age was 8.43 ± 4.06 years (minimum 3; maximum 18). Three patients had a positive family history of ASD. Based on the autism severity ranking considering the CARS points, the majority of the features in the working group was determined as severe. Sequencing of the NRXN1 gene revealed two different mutations, namely, S14L and L748I (Table 1).
Table 1

Clinical characteristics and genetic results of the patient group. (ASD: autism spectrum disorder; CARS: Childhood Autism Rating Scale.)

PatientSex-AgeFamily History of ASDCARSCARS ScoresMutationsMotherFather
P1M-1737severely autistic
P2M-430mild/moderately autisticS14L/-S14L/-
P3M1049.5severely autistic
P4F-546severely autistic
P5M-1531mild/moderately autistic
P6M-644severely autistic
P7M-541.5severely autistic
P8M-938.5severely autistic
P9M-741.5severely autisticL748I/-L748I/-
P10M-1142.5severely autistic
P11F-847.5severely autistic
P12M-1032mild/moderately autistic
P13M-1526mild/moderately autistic
P14M-451severely autistic
P15M-647severely autistic
P16M-6positive41.5severely autistic
P17M-1037severely autistic
P18F-637severely autistic
P19M-1038severely autistic
P20M-843severely autistic
P21M-937severely autistic
P22M-8positive31.5mild/moderately autistic
P23M-1850severely autistic
P24M-446.5severely autistic
P25F-14positive31mild/moderately autistic
P26M-935mild/moderately autistic
P27M-830mild/moderately autistic
P28M-353severely autistic
P29M-439severely autistic
P30F-442severely autistic
Clinical characteristics and genetic results of the patient group. (ASD: autism spectrum disorder; CARS: Childhood Autism Rating Scale.)

Discussion

The ASD is a neurodevelopmental disorder characterized by deficits in social communication and the presence of repetitive patterns of behavior, activity and interests [16]. The heritability of ASD is 90.0% and there is an increased recurrence risk in first-degree relatives of more than 20-fold [7,8]. The aim of this study was to better understand the role of the NRXN1 gene that is listed as one of the two strong candidate genes in SFARIGENE (an important database for autism) [12]. Neurexin proteins are the cell surface receptors that tie neuroligin (NLGN). The Ca2+-dependent neurexin/ neuro-ligin complex is present at synapses in the CNS is required for efficient neuro-transmission, and is involved in the formation of synaptic contacts. The NRXN1 is a gene that expresses NRXN1 (OMIM:600565) protein, located on chromosome 2 at position 2p16.3, has 22 ex-ons, encodes 1477 amino acids, has 7505 bp. Small and large deletions in the NRXN1 gene, could play a role in the etiology of ASD. Additionally, missense and nonsense mutations in the NRXN1 gene could play a role in the pathogenesis of this disorder [17,18]. Mild/moderately and severely autistic patients were involved in our study. There were more male cases than female cases in the study parallel to the rates notified in the autism literature [3,10]. Two known mutations were described in two different cases. S14L (SFARIGENE Variant ID: GEN179R001) in patient P2 and L748I (SFARIGENE Variant ID: GEN179R007) in patient P9. S14L [17] and L748I [18] mutations have been described in patients with autism before. Both of these mutations were inherited from their father. The fathers of the children who carried the mutations were reevaluated psychiatrically and autism-spectrum quotient (AQ) questionnaire [19,20], which has been used extensively to measure the broader autism phenotype (BAP), was applied to the fathers. The father of patient P2 did not have any psychiatric diagnosis and symptoms. His total AQ score was 22 (social skill: 6 points, attention switching: 3 points, attention to detail: 4 points, communication: 4 points, imagination: 5 points). This may indicate a reduced penetrance in the NRXN1 gene. Reduced penetrance in the NRXN1 gene has been reported before [18-21]. The father of patient P9 had attention deficit and hyperactivity disorder (ADHD) symptoms and mild obsessions. His total AQ score was 13 (social skill: 4 points, attention switching: 4 points, attention to detail: 3 points, communication: 1 points, imagination: 1 points). The ADHD and sub-threshold obsessive compulsive symptoms in one father (father of P9) was determined as remarkable. Genetic relatives of people with autism may show milder expression of characteristic traits for autism, referred to as the BAP [22]. Up to now, the S14L mutation has been detected in four subjects with ASD and not in 1201 controls [17]. The S14L mutation was described in two siblings in two families and the mutations in these two families were inherited from their father. In one of family, there was a boy who met the autism diagnostic interview-revised (ADI-R) criteria and his sister with central auditory processing problem, and decreased social interaction. Their father, who carried a heterozygous S14L mutation, had a learning disability. In the other family there was also a boy who met the ADI-R criteria and his brother had learning disability and hyper-activity [17]. The L748I mutation was previously identified in two families with ASD. There were four ASD patients in these two families; the L748I mutation was detected in three of four ASD patients, and also detected in one of two unaffected individuals. Because of that, this mutation was evaluated as an ASD susceptibility allele showing incomplete penetrance [18].

Conclusions

Two of 30 (6.7%) ASD patients were diagnosed with NRXN1 mutations in this study. It indicated that variants in the NRXN1 gene might confer a risk in developing non syndromic ASD. However, due to the reduced penetrance in the gene, the causal role of the NRXN1 gene mutations must be evaluated carefully in all cases.
  17 in total

1.  High frequency of neurexin 1beta signal peptide structural variants in patients with autism.

Authors:  Jinong Feng; Richard Schroer; Jin Yan; Wenjia Song; Chunmei Yang; Anke Bockholt; Edwin H Cook; Cindy Skinner; Charles E Schwartz; Steve S Sommer
Journal:  Neurosci Lett       Date:  2006-10-10       Impact factor: 3.046

Review 2.  What is known about autism: genes, brain, and behavior.

Authors:  Susan L Santangelo; Katherine Tsatsanis
Journal:  Am J Pharmacogenomics       Date:  2005

Review 3.  Autism.

Authors:  Susan E Levy; David S Mandell; Robert T Schultz
Journal:  Lancet       Date:  2009-10-12       Impact factor: 79.321

4.  Essential versus complex autism: definition of fundamental prognostic subtypes.

Authors:  J H Miles; T N Takahashi; S Bagby; P K Sahota; D F Vaslow; C H Wang; R E Hillman; J E Farmer
Journal:  Am J Med Genet A       Date:  2005-06-01       Impact factor: 2.802

5.  When father doesn't know best: selective disagreement between self-report and informant report of the broad autism phenotype in parents of a child with autism.

Authors:  Noah J Sasson; Daniel J Faso; Morgan Parlier; Julie L Daniels; Joseph Piven
Journal:  Autism Res       Date:  2014-10-22       Impact factor: 5.216

Review 6.  Epidemiology of pervasive developmental disorders.

Authors:  Eric Fombonne
Journal:  Pediatr Res       Date:  2009-06       Impact factor: 3.756

7.  Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS).

Authors:  E Schopler; R J Reichler; R F DeVellis; K Daly
Journal:  J Autism Dev Disord       Date:  1980-03

8.  Disruption of neurexin 1 associated with autism spectrum disorder.

Authors:  Hyung-Goo Kim; Shotaro Kishikawa; Anne W Higgins; Ihn-Sik Seong; Diana J Donovan; Yiping Shen; Eric Lally; Lauren A Weiss; Juliane Najm; Kerstin Kutsche; Maria Descartes; Lynn Holt; Stephen Braddock; Robin Troxell; Lee Kaplan; Fred Volkmar; Ami Klin; Katherine Tsatsanis; David J Harris; Ilse Noens; David L Pauls; Mark J Daly; Marcy E MacDonald; Cynthia C Morton; Bradley J Quade; James F Gusella
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

Review 9.  Autism spectrum disorders--a genetics review.

Authors:  Judith H Miles
Journal:  Genet Med       Date:  2011-04       Impact factor: 8.822

10.  Clinical genetics evaluation in identifying the etiology of autism spectrum disorders.

Authors:  G Bradley Schaefer; Nancy J Mendelsohn
Journal:  Genet Med       Date:  2008-04       Impact factor: 8.822

View more
  6 in total

1.  The influence of NRXN1 on systemizing and the brain structure in healthy adults.

Authors:  Yuka Shiota; Izumi Matsudaira; Hikaru Takeuchi; Chiaki Ono; Hiroaki Tomita; Ryuta Kawashima; Yasuyuki Taki
Journal:  Brain Imaging Behav       Date:  2021-09-16       Impact factor: 3.224

2.  Prospects of Zinc Supplementation in Autism Spectrum Disorders and Shankopathies Such as Phelan McDermid Syndrome.

Authors:  Simone Hagmeyer; Ann Katrin Sauer; Andreas M Grabrucker
Journal:  Front Synaptic Neurosci       Date:  2018-05-23

Review 3.  Paving the Way toward Personalized Medicine: Current Advances and Challenges in Multi-OMICS Approach in Autism Spectrum Disorder for Biomarkers Discovery and Patient Stratification.

Authors:  Areej G Mesleh; Sara A Abdulla; Omar El-Agnaf
Journal:  J Pers Med       Date:  2021-01-13

4.  Investigation of Copy Number Variation by arrayCGH in Turkish Children and Adolescents Diagnosed with Autism Spectrum Disorders.

Authors:  Işık Görker; Hakan Gürkan; Selma Ulusal; Engin Atli; Güçlü Ayaz; Cansın Ceylan; Hilmi Tozkir; Mengühan Araz Altay; Ali Erol; Nazike Yildiz; Ceren Direk; Hilal Akköprü; Neriman Kilit; Hasan Cem Aykutlu; Leyla Bozatli; Zeki Çelik; Kıvanç Kudret Berberoğlu
Journal:  Noro Psikiyatr Ars       Date:  2018-04-26       Impact factor: 1.339

Review 5.  Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach.

Authors:  Bridget A Fernandez; Stephen W Scherer
Journal:  Dialogues Clin Neurosci       Date:  2017-12       Impact factor: 5.986

Review 6.  Reaching into the toolbox: Stem cell models to study neuropsychiatric disorders.

Authors:  Jack T Whiteley; Sarah Fernandes; Amandeep Sharma; Ana Paula D Mendes; Vipula Racha; Simone K Benassi; Maria C Marchetto
Journal:  Stem Cell Reports       Date:  2022-01-20       Impact factor: 7.294

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.